Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
- 30 June 2001
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 15 (2), 85-95
- https://doi.org/10.1054/blre.2001.0152
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory TyrosinesJournal of Biological Chemistry, 2000
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Abl tyrosine protein kinaseSeminars in Immunology, 1995
- Modular binding domains in signal transduction proteinsCell, 1995
- Cell Cycle—Regulated Binding of c-Abl Tyrosine Kinase to DNAScience, 1992
- Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populationsCell, 1991
- BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.Molecular and Cellular Biology, 1991
- The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localizationCell, 1989
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973